SALYA AKMASI (DROOLING); DEĞERLENDİRME VE TEDAVİ YÖNTEMLERİ

Yıl 2018, Cilt: 3 Sayı: 1, 22 - 28, 30.03.2018

Çetin Sayaca

Öz

Salya akması serebral palsi, down sendromu veya
nörodejeneratif hastalığı olan kişilerde, hastalığın seyrini etkilemese de
kişiyi ve ailesini psikososyal yönden etkileyen önemli bir problemdir. Bu
problemin tedavisinde, fizyoterapi ile oro-motor tedavi, cerrahi tedavi,
medikal tedavi, minimal invaziv yöntemler, radyoterapi, tamamlayıcı ve
alternatif tedavi yöntemleri kullanılmaktadır. Şiddetli nörodejeneratif
hastalığı veya mental problemi olmayan hastalarda cerrahi tedaviden önce
fizyoterapi tercih edilmektedir. Bu hastalarda, ilaç tedavisi de
kullanılabilmektedir. Ancak uzun dönem kullanımı uygun olmayabilir. Minimal
invaziv tedaviler konservatif tedaviler ile birlikte kullanılmaktadır. Bu
yöntemlerin etki süresi, uygun miktarı ve tekrarlama sıklığı hakkında
literatürde yeterli bilgi bulunmamaktadır. Radyoterapi, çocuklar için bazı
riskler içermektedir. Bu araştırmanın amacı, güncel literatür üzerinde salya
akması ve tedavi yöntemlerini tekrar gözden geçirmektir.

Anahtar Kelimeler

Hipersalivasyon, Salya Akması, Rehabilitasyon

Kaynakça

• 1.Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: A review of theetiology and management options. Oral Surgery, Oral Medicine, Oral pathology, oral Radiology and Endodontology. 2006;101(1):48-57. 2.Naghavi SE, Jalali MM. Management of drooling for patients in the north of Iran: Analysis of the surgical management. JRMS. 2010;15:1-5. 3.Hall JE. Secretory functions of the alimentarytract. In Hall JE, ed. Guyton&HallTextbook of Medical Physiology, 12th ed. Philadelphia: SaundersElsevier; 2011. 4.Freeman JJ, Altieri RH, Baptiste HJ, Kuo T, Crittenden S, Fogarty K, et al. Evaluation and management of sialorrhea of pregnancy with concomitant hyperemesis. J Natl. Med. Assoc. 1994;86:704-708. 5.Humphrey SP, Williamson RT. A review of saliva: Normal composition, flow, and function. J ProsthetDent. 2001;85:162-169. 6.Cate ART. Oral Histology: development, structure and function. 5th ed. St. Louis, MO: Mosby-YearBook, Inc; 1998. 7.Nunn JH. Drooling: Review of the literatüre and proposals for management. Journal of Oral Rehabilitation 2001; 27 (9): 735-743. 8.Zolothukin S. Metabolichormones in saliva: origins and functions. Oral Dis. 2013;19:219-229. 9.Rudney JD, Smith QT. Relationships between levels of lysozyme, lactoferrin, salivaryperoxidase, and secretory immunoglobulin. A in stimulated parotidsaliva. Infect. Immun. 1985;49:469-475. 10.Walsh LJ. Clinical aspects of salivary biology for the dental clinician. Int. Dent. S. Afric. 2007;9:22-41. 11.Lal D, Hotaling AJ. Drooling. Curr. Opin. Otolaryngol Head Neck Surg. 2006;14:381-386. 12.Miranda-Rius J, Brunet-Llobet L, Lahor-Soler E, Farre M. Salivary Secretory Disorders, Inducing Drugs, and Clinical Management. Int. J. Med. Sci. 2015;12:811-824. 13.Proulx M, de Courval FP, Wiseman MA, Panisset M. Salivary production in Parkinson’s disease. Mov. Disord. 2005;20:204-207. 14.Bagheri H, Damase-Michel C, Lapeyre-Mestre M, Cismondo S, O Connell D, Senard JM, et al. A study of salivary secretion in Parkinson’s disease. Clin. Neuropharmacol. 1999;22:213-215. 15.Brei TJ. Management of drooling. Seminars in Pediatric Neurology. 2003;10(4):265-270. 16.Muammer R, Muammer K. Drooling in Disabled Children Evaluation and Management. Yeditepe Medical Journal. 2009;10:188-193. 17.Tahmassebi JF, Curzon ME. Prevalence of drooling in children with cerebral palsy attending special schools. Dev. Med. Child. Neurol. 2003;45:613-617. 18.Sullivan PB, Lambert B, Rose M, Ford-Adams M, Johnson A, Griffiths P. Prevalence and severity of feding and nutritional problems in children with neurological impairment: Oxford Feeding Study. Dev. Med. Child. Neurol. 2000;42:674-680. 19.Lespargot A, Langevin MF, Muller S, Guillemont S. Swallowing disturbances associated with drooling in cerebral palsied children. Dev. Med. Child. Neurol. 1993;35:298-304. 20.Senner JE, Logemann J, Zecker S. Drooling, Saliva production, and swallowing in cerebral palsy. Developmental Medicine & Child neurology. 2004;46:801-806. 21.Camp-Bruno JA, Winsberg BG, Green-Parsons AR, Abrams JP. Efficacy of Benztropine Therapy for Drooling. Dev. Med. Child Neurol. 1989;31:309-319. 22.Suskind DL, Tilton A. Clinical study of botulinum-A toxin in thetreatment of sialorrhea in children with cerebral palsy. Laryngoscope 2002;112:73-81. 23.Hotaling AJ, Madgy DN, Kuhns LR, Filipek L, Belenky WM. Postoperative technetium scanning in patients with submandibuler duct diversion. Arch Otolaryngol Head Neck Surg. 1992;118:1331-1333. 24.Jongerius PH, van den Hoogen FJA, vanLimbeekJ, Gabreëls FJ, vanHulst K, Rotteveel JJ. Effect of botulinumtoxin in thetreatment of drooling: a controlled clinical trial. Pediatrics. 2004;114(3):620-627. 25.Hotaling AJ, Madgy DN, Kuhns LR, Filipek L, BelenkyWM. Postoperative technetium scanning in patients with submandibular duct diversion. Arch Otolaryngol Head Neck Surg. 1992;118:1331-1333. 26.Jongerius PH, vanLimbeekJ, Rotteveel JJ. Assessment of salivary flow rate: biologicv ariation and measure error. Laryngoscope. 2004;114:1801-1804. 27.Erasmus CE, Van Hulst K, Rotteveel LJ. Drooling in Cerebral Palsy: Hypersalivation or Dysfunctional Oral Motor Control? Developmental Medicine& Child Neurology. 2009;51:454–459. 28.Freudenreich O. Drug induced sialorrhea. Drugs of Today (Barc). 2005;41:411-418. 29.Crysdale WS, McCann C, Roske L, Joseph M, Semenuk D, ChaitP.Salivacontrolissues in theneurologicallychallenged: a 30 yearexperience in teammanagement. Int J Pediatr Otorhinolaryngol 2006; 70: 519-527. 30.Crysdale WS. Themanagement of drooling. In: Bluestone CD, Stool SE, Alper CM, et al. editors. Pediatricotolaryngology, 4th ed. Philadelphia: Saunders; 2002. p.1138-1148. 31.Hockstein NG, Samadi DS, Gendron K, Handler SD. Sialorrhea: a management challenge. Am Fam Physician 2004; 69: 2628-2634. 32.Ray SA, Bundy AC, Nelson DL. Decreasing drooling through techniques to facilitate mouth closure. American Journal of Occupational Therapy 1983;37:749-753. 33.Koheil R, Sochaniwsky A, Bablich K, Kenny DJ, Milner M. Biofeedback techniques and behaviour modification in the conservative remediation of drooling by children with cerebral palsy. Dev Med Child Neurol. 1987;29:19-26. 34.McCracken A. Drool control and tongue thrust therapy for the mentally retarded. American Journal of Occupational Therapy. 1978;32:79-85. 35.Cole LM. Neuromuscular Stimulation for Moebius Syndrome Case Study. Advance for Speech-Language Pathologists & Audiologists. 2007;17(10):11. 36.Hoyer H, Limbrock GJ. Orofacial regulation therapy in children with Down syndrome, using the method and appliances of Castillo-Morales. ASDC J Dent. Child. 1990;57:442-444. 37.Limbrock GJ, Fischer-Brandies H, Avalle C. Castillo-Morales Orofacial Therapy: Treatment of 67 Children with Down Syndrome. Developmental Medicine and Child Neurology. 1991;33:296-303. 38.Akgun OM, Basak F. Drooling and management of droolıng. Atatürk Üniv. Diş Hek. Fak. Derg. J. Dent. Fac. Atatürk Uni. 2011;21(2):134-140. 39.Guggenheimer J, Moore PA. Xerostomia. Etiology, Recognition and Treatment. J Am. Dent. Assoc. 2003;134:61-69. 40.Sennhauser FH, Schwarz HP. Toxicpsychosis from transdermal scopolamine in a child. Lancet. 1986;2:1033. 41.Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinumtoxina for treatment of drooling. Neurology. 2003;61:1279-1281. 42.Racette BA, Good L, Sagitto S, Perlmutter JS. Botulinumtoxin B reduces sialorrhea in Parkinsonism. Mov. Disord. 2003;18:1059-1061. 43.Ondo WG, Hunter C, Moore W. A double-blind placebo-controlledtrial of botulinumtoxin B for sialorrhea in Parkinson’s disease. Neurology. 2004;62:37-40. 44.Ellies M, Laskawi R, Rohrbach-Volland S, Arglebe C. Up-to-datereport of botulinumtoxin therapy in patients with drooling caused by different etiologies. J Oral Maxillofac Surg. 2003;61:454 –457. 45.Chang CJ, May-KuenWong AA. Intraductal laser photocoagulation of the bilateral parotidducts for reduction of drooling in patients with cerebral palsy. Plast. Reconstr. Surg. 2001;107:907-913. 46.Sellars SL. Surgery of sialorrhoea. J Laryngol Otol. 1985; 99: 1107-1109. 47.Grant R, Miller S, Simpson D, Lamey PJ, Bone I. The effect of chordatympani section on ipsilateral and contralateral salivary secretion and taste in man. J Neurol. Neurosurg. Psychiatry. 1989;52:1058-1062. 48.Dundas DF, Peterson RA. Surgical treatment of drooling by bilateral parotid ductligation and submandibular gland resection. Plast. Reconstr. Surg. 1979;64:47-51. 49.Shott SR, Myer CM, Cotton RT. Surgical management of sialorrhea. Otolaryngol Head Neck Surg. 1989;101:47-50. 50.Borg M, Hirst F. The role of radiation therapy in the management of sialorrhea. Int. J. Radiation Oncol. Biol. Phys. 1998;41:1113-1119. 51.Assouline A, Levy A, Abdelnour-Mallet M, Gonzalez-Bermejo J, Lenglet T, Le Forestier N, et al. Radiation therapy for hypersalivation: a prospective study in 50 amyotrophic lateral sclerosis patients. Int. J. Radiat. Oncol. Biol. Phys. 2014;88:589-595. 52.PerezLloret S, Rey MV, Pavy-Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin Emerg Drugs. 2013;18:39-53. 53.Wong V, Sun JG, Wong W. Traditional Chinese medicine (tongue acupuncture) in children with drooling problems. Pediatr Neurol. 2001;25:47-54.